fenofibrate has been researched along with Arteriosclerosis in 41 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "Twenty-two patients with mixed hyperlipidemia participated." | 2.70 | Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. ( Ceska, R; Grauová, B; Kozich, V; Melenovský, V; Stulc, T, 2001) |
| "A fenofibrate-induced increase of HDL-C in 20 low-HDL subjects was associated with a significant reduction of plasma sICAM-1 and sE-selectin concentrations." | 2.70 | Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. ( Calabresi, L; Dmitrieff, C; Franceschini, G; Gomaraschi, M; Omoboni, L; Villa, B, 2002) |
| "Fenofibrate is a broad spectrum lipid-lowering agent able to produce substantial reductions in plasma triglyceride and low density lipoprotein (LDL) and an increase in high density lipoprotein (HDL)." | 2.40 | Overview of fenofibrate. ( Packard, CJ, 1998) |
| "Fenofibrate treatment in apo E-KO mice paradoxically increased total cholesterol and TG by 65% and 44%, respectively, and decreased HDL-cholesterol levels by 35% as compared with controls." | 1.33 | Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. ( Bahadori, B; Declercq, V; Khademi, H; Moghadasian, MH; Moshtaghi-Kashanian, GR; Yeganeh, B, 2005) |
| "The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes." | 1.31 | Status report of lipid-lowering trials in diabetes. ( Armitage, J; Betteridge, DJ; Colhoun, H, 2000) |
| "Twenty patients with uncomplicated hyperlipidemia but no atherosclerosis, 20 patients with hyperlipidemia plus clear atherosclerosis, and 40 matched controls were studied." | 1.31 | Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. ( Belgore, FM; Blann, AD; Conri, C; Constans, J; Lip, GY, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.88) | 18.7374 |
| 1990's | 14 (34.15) | 18.2507 |
| 2000's | 25 (60.98) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duez, H | 1 |
| Chao, YS | 1 |
| Hernandez, M | 1 |
| Torpier, G | 1 |
| Poulain, P | 1 |
| Mundt, S | 1 |
| Mallat, Z | 1 |
| Teissier, E | 1 |
| Burton, CA | 1 |
| Tedgui, A | 1 |
| Fruchart, JC | 1 |
| Fiévet, C | 1 |
| Wright, SD | 1 |
| Staels, B | 2 |
| Srivastava, RA | 1 |
| Dierkes, J | 1 |
| Westphal, S | 1 |
| Luley, C | 1 |
| Jokinen, V | 1 |
| Ukkola, O | 1 |
| Airaksinen, KE | 1 |
| Koistinen, JM | 1 |
| Ikäheimo, MJ | 1 |
| Kesäniemi, YA | 1 |
| Huikuri, HV | 1 |
| Watts, GF | 1 |
| Tsimihodimos, V | 1 |
| Kostoula, A | 1 |
| Kakafika, A | 1 |
| Bairaktari, E | 1 |
| Tselepis, AD | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, M | 1 |
| Yamazaki, H | 1 |
| Fujino, H | 1 |
| Kanazawa, M | 1 |
| Tamaki, T | 1 |
| Sato, F | 1 |
| Suzuki, M | 1 |
| Kitahara, M | 1 |
| Ruban, NV | 1 |
| Zhao, SP | 1 |
| Li, J | 1 |
| Xu, Z | 1 |
| Wu, J | 1 |
| Li, Q | 1 |
| Ye, H | 1 |
| Sebestjen, M | 1 |
| Keber, I | 1 |
| Zegura, B | 1 |
| Simcic, S | 1 |
| Bozic, M | 1 |
| Fressart, MM | 1 |
| Stegnar, M | 1 |
| Yeganeh, B | 2 |
| Moshtaghi-Kashanian, GR | 2 |
| Declercq, V | 2 |
| Moghadasian, MH | 2 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Han, SH | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Seo, YH | 1 |
| Choi, IS | 1 |
| Shin, EK | 1 |
| Khademi, H | 1 |
| Bahadori, B | 1 |
| Segarra Domènech, J | 1 |
| Santafé Oroz, J | 1 |
| Kritchevsky, D | 1 |
| Singer, D | 1 |
| Klurfeld, DM | 1 |
| Saitoh, K | 2 |
| Mori, T | 2 |
| Kasai, H | 2 |
| Nagayama, T | 2 |
| Tsuchiya, A | 1 |
| Ohbayashi, S | 2 |
| Schonfeld, G | 1 |
| Millán Núñez Cortés, J | 1 |
| Alvarez-Sala Walther, LA | 1 |
| de Oya Otero, M | 1 |
| Packard, CJ | 3 |
| Madej, A | 2 |
| Okopien, B | 2 |
| Kowalski, J | 2 |
| Zielinski, M | 2 |
| Wysocki, J | 2 |
| Szygula, B | 1 |
| Kalina, Z | 2 |
| Herman, ZS | 1 |
| Szyguła, B | 1 |
| Herman, Z | 1 |
| Sinzinger, H | 1 |
| Marx, N | 3 |
| Sukhova, GK | 1 |
| Collins, T | 1 |
| Libby, P | 2 |
| Plutzky, J | 2 |
| Stejskal, D | 1 |
| Růzicka, V | 1 |
| Bartek, J | 1 |
| Bratus', VV | 1 |
| Talaieva, TV | 1 |
| Lomakovs'kyĭ, OM | 1 |
| Tretiak, IV | 1 |
| Radalovs'ka, NV | 1 |
| Betteridge, DJ | 1 |
| Colhoun, H | 1 |
| Armitage, J | 1 |
| Deighan, CJ | 1 |
| Caslake, MJ | 1 |
| McConnell, M | 1 |
| Boulton-Jones, JM | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Xie, ML | 1 |
| Gu, ZL | 1 |
| Chen, KJ | 1 |
| Zhou, WX | 1 |
| Guo, CY | 1 |
| Yamashita, T | 1 |
| Nakamura, H | 1 |
| Blann, AD | 1 |
| Belgore, FM | 1 |
| Constans, J | 1 |
| Conri, C | 1 |
| Lip, GY | 1 |
| Hombach, V | 2 |
| Stulc, T | 1 |
| Melenovský, V | 1 |
| Grauová, B | 1 |
| Kozich, V | 1 |
| Ceska, R | 1 |
| Kehrle, B | 1 |
| Kohlhammer, K | 1 |
| Grüb, M | 1 |
| Koenig, W | 1 |
| Calabresi, L | 1 |
| Gomaraschi, M | 1 |
| Villa, B | 1 |
| Omoboni, L | 1 |
| Dmitrieff, C | 1 |
| Franceschini, G | 1 |
| Ruhn, G | 1 |
| Slimane, MN | 1 |
| Bouslama, A | 1 |
| Maatoug, F | 1 |
| Hammami, M | 1 |
| Ben Farhat, MH | 1 |
| Ol'binskaia, LI | 1 |
| Vartanova, OA | 1 |
| Aleksandrovskaia, TN | 1 |
| Shaldaeva, VV | 1 |
10 reviews available for fenofibrate and Arteriosclerosis
| Article | Year |
|---|---|
Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.
Topics: Arteriosclerosis; Fenofibrate; Folic Acid; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Kidne | 2003 |
[Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
Topics: Animals; Arteriosclerosis; Cholesterol; Cholesterol, VLDL; Citrus paradisi; Clinical Trials as Topic | 2004 |
[Pharmacologic therapy of atherosclerosis (I). Current possibilities].
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Ge | 1983 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
[Fenofibrate and arteriosclerosis. The new developments of the last 5 years].
Topics: Arteriosclerosis; Clinical Trials as Topic; Fenofibrate; Humans; Hypolipidemic Agents; Lipids; Throm | 1995 |
Overview of fenofibrate.
Topics: Apolipoprotein C-III; Apolipoproteins C; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hy | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagu | 1998 |
[Fenofibrate].
Topics: Animals; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Age | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
[ Lipids--lipoproteins--apolipoproteins--risk markers in atherosclerosis].
Topics: Adult; Apolipoproteins; Arteriosclerosis; Biomarkers; Fenofibrate; Humans; Lipoproteins; Middle Aged | 1992 |
10 trials available for fenofibrate and Arteriosclerosis
| Article | Year |
|---|---|
Temporal changes in cardiovascular autonomic regulation in type II diabetic patients: association with coronary risk variables and progression of coronary artery disease.
Topics: Adult; Aged; Arteriosclerosis; Autonomic Nervous System; Coronary Angiography; Diabetes Mellitus, Ty | 2003 |
Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Arteriosclerosis; Biomarkers; C-Reactive Prot | 2004 |
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Topics: Adult; Arteriosclerosis; Blood Coagulation; Blood Coagulation Factors; Body Weight; C-Reactive Prote | 2004 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Thera | 2005 |
Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
Topics: Adult; Arteriosclerosis; Cytokines; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypol | 1998 |
[Levels of tumor necrosis factor alpha in serum of patients with hyperlipoproteinemia IIB before and after micronized fenofibrate therapy].
Topics: Adult; Apolipoproteins B; Arteriosclerosis; Cholesterol; Drug Compounding; Female; Fenofibrate; Huma | 1998 |
[Serum leptin, early atherosclerosis and hypolipidemia (a new, previously undescribed effect of pravastatin, a hypolipemic agent)].
Topics: Adipose Tissue; Age of Onset; Arteriosclerosis; Body Mass Index; Female; Fenofibrate; Humans; Hypoli | 1998 |
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cross-Over Studies; Female; | 2001 |
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
Topics: Arteriosclerosis; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Folic | 2001 |
Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.
Topics: Analysis of Variance; Arteriosclerosis; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; E | 2002 |
21 other studies available for fenofibrate and Arteriosclerosis
| Article | Year |
|---|---|
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins E; Arteriosclerosis; Cholesterol; Fenofibrate; Humans; | 2002 |
Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen.
Topics: Animals; Apolipoprotein A-I; Arteriosclerosis; ATP-Binding Cassette Transporters; Cholic Acid; Estra | 2002 |
Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives.
Topics: Arteriosclerosis; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Fenofibrate; Gene Expre | 2004 |
[Systemic inflammatory process as an etiological factor in increase of atherogenic potential of plasma].
Topics: Animals; Arteriosclerosis; Disease Models, Animal; Fenofibrate; Hypolipidemic Agents; Lipid Peroxide | 2004 |
Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits.
Topics: Adipose Tissue; Animals; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Diet; Enzyme-Linked Im | 2004 |
Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, HDL; Diet; Feno | 2005 |
Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Cholesterol, | 2005 |
Influence of hypocholesterolemic drugs on aortic cholesterol esterase in rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Carboxylic Ester Hydrolases; Cholesterol | 1984 |
[Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. I: Anti-atheromatous effects are independent of its hypolipidemic effect in cholesterol-fed rabbits].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Diet, Atherogenic; Disease Models, Animal; Fenofibrate; | 1995 |
[Anti-atheromatous effects of fenofibrate, a hypolipidemic drug. II: Anti-atheromatous effects are independent of its hypolipidemic effect in hereditary hyperlipidemic rabbits].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Fenofibrate; Gene Deletion; Hyperlipidemias; Hypolipidem | 1995 |
LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 1996 |
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.
Topics: Anticholesteremic Agents; Arteriosclerosis; Carotid Arteries; Cell Adhesion; Dose-Response Relations | 1999 |
[Modified lipoproteins--their types and role in atherogenesis].
Topics: Adult; Animals; Arteriosclerosis; Child; Child, Preschool; Chronic Disease; Coronary Artery Disease; | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease | 2000 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
Effect of lipanthyl on mRNA expression of endothelin-1 and nitric-oxide synthase in atherosclerotic vessel wall in rabbits.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Endothelin-1; Fenofibrate; Hypolipidemic Agents; Male; | 2000 |
Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Endothelial Growth Factors; Fatty Acids, Mo | 2001 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate | 2002 |
Relation between arteriographically diagnosed femoral atherosclerosis and serum lipids. Prevalence and treatment in hyperlipidaemic subjects.
Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Drug Therapy, Combination; Femoral | 1992 |
[The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
Topics: Arteriosclerosis; Drug Evaluation; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperl | 1991 |